RNA Leaders Europe Congress
March 13–14, 2024
Join Genedata experts at the RNA Leaders Europe Congress in Basel, Switzerland.
Don't miss the opportunity to see how Genedata Screener® captures data from all assays, regardless of therapeutic modality or area. It automates analysis of even the most complex assays, on a single platform and in a harmonized manner, to ensure high result quality and better decision-making.
Recommended Panel Discussions
Work smarter not harder – How to improve efficiency in data handling during RNA drug discovery Work smarter not harder – How to improve efficiency in data handling during RNA drug discovery
Moderated by Ming Wang, Business Development Manager, Genedata, Switzerland
Next Generation RNA Innovation: Utilizing Big Data
Wednesday, 13 March, 2024 | 16:40 - 17:25
Jacques Dumas, CSO, Arrakis Therapeutics
Dimitar Yonchev, Data Engineer, Roche
Developing a new RNA drug from scratch, be it an ASO, an mRNA or RNA-targeting small molecule, is a multi-faceted endeavor, requiring several areas of expertise and several layers of experimental assays in order to tease out the best candidates. As such, experimental data is handled by various different people and is coming in from different directions. In most cases, data is processed in a manual manner, and is saved, analyzed and compiled in a series of disparate Excel sheets. With the reliance on manual input at several stages of data handling, data processing can be time- and labor-intensive, where the results itself becomes vulnerable to bias and human-error. This issue becomes exaggerated when institutions scale up their screening throughput and end up generating much larger volumes of data than ever before. Anecdotally, one group reports spending 40 hours on data analysis, including time for data transfer from the instrument, quality control, data processing, data compilation and reporting, per screening campaign.
- How can this problem be overcome?
- How can institutions screen for the best sequences, chemistries, conjugations or LNP formulations, without being overwhelmed by the data?
In the age of 'data-centricity', what are RNA-focused institutions doing to make sure they get the most out of their data?
Recommended Oral Presentations
Leading through Data – Learnings from Digital Champions
Ming Wang, Business Development Manager, Genedata, Switzerland
Next Generation RNA Innovation: Biomarkers & BioInformatics
Wednesday, 13 March 2024 | 11:50 am – 12:00 am
Here we will discuss some of the trends we have been noticing across the RNA drug landscape, in relation to the 'digitalization' of R&D efforts. What are the aims of digitalization, and how are institutions trying to make the most of their data, particularly when driven by the ambition to upscale? How are different types of organizations, i.e. pharma, biotech or CROs, who in addition to having different business aims may also be at different stages of their digitalization journeys, addressing these topics? In our presentation we hope to provide some insights.